-
1
-
-
0026625220
-
A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A Cooperative Group Study
-
Loehrer P, Einhorn LH, Elson PJ, Crawford ED, Kuebler P, Tannock I, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol 1992;10:1066-73.
-
(1992)
J Clin Oncol
, vol.10
, pp. 1066-1073
-
-
Loehrer, P.1
Einhorn, L.H.2
Elson, P.J.3
Crawford, E.D.4
Kuebler, P.5
Tannock, I.6
-
2
-
-
0025297496
-
A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors
-
Logothetis CJ, Dexeus F, Finn L, Sella A, Amato RJ, Ayala AG, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastastic urothelial tumors. J Clin Oncol 1990;8:1050-5.
-
(1990)
J Clin Oncol
, vol.8
, pp. 1050-1055
-
-
Logothetis, C.J.1
Dexeus, F.2
Finn, L.3
Sella, A.4
Amato, R.J.5
Ayala, A.G.6
-
3
-
-
0021910302
-
Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumors
-
Sternberg CN, Yagoda A, Scher HI, Watson RC, Ahmed T, Weiselberg LR, et al. Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumors. J Urol 1985;133:403-7.
-
(1985)
J Urol
, vol.133
, pp. 403-407
-
-
Sternberg, C.N.1
Yagoda, A.2
Scher, H.I.3
Watson, R.C.4
Ahmed, T.5
Weiselberg, L.R.6
-
4
-
-
0024817806
-
M-VAC for advanced transitional cell carcinoma of the urothelium: Efficacy, and patterns of response and relapse
-
Sternberg CN, Yagoda A, Scher HI, Watson RC, Geller N, Herr HW, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. Cancer 1989;64:2448-58.
-
(1989)
Cancer
, vol.64
, pp. 2448-2458
-
-
Sternberg, C.N.1
Yagoda, A.2
Scher, H.I.3
Watson, R.C.4
Geller, N.5
Herr, H.W.6
-
5
-
-
0032795983
-
Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma
-
Dodd PM, McCaffrey JA, Herr H, Mazumdar M, Bacik J, Higgins G, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. Clin Oncol 1999;17(8):2546.
-
(1999)
Clin Oncol
, vol.17
, Issue.8
, pp. 2546
-
-
Dodd, P.M.1
McCaffrey, J.A.2
Herr, H.3
Mazumdar, M.4
Bacik, J.5
Higgins, G.6
-
6
-
-
0032887956
-
Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy
-
Bajorin DF, Dodd PM, Mazumdar M, Fazzari M, McCaffrey JA, Scher HI, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol 1999;17(10):3173-81.
-
(1999)
J Clin Oncol
, vol.17
, Issue.10
, pp. 3173-3181
-
-
Bajorin, D.F.1
Dodd, P.M.2
Mazumdar, M.3
Fazzari, M.4
McCaffrey, J.A.5
Scher, H.I.6
-
7
-
-
0030794516
-
Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study
-
Saxman SB, Propert KJ, Einhorn LH, Crawford ED, Tannock I, Raghavan D, et al. Long-term follow-up of a phase III intergroup study of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a cooperative group study. J Clin Oncol 1997;15(7):2564-9.
-
(1997)
J Clin Oncol
, vol.15
, Issue.7
, pp. 2564-2569
-
-
Saxman, S.B.1
Propert, K.J.2
Einhorn, L.H.3
Crawford, E.D.4
Tannock, I.5
Raghavan, D.6
-
8
-
-
0025906244
-
Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy
-
Geller NL, Sternberg CN, Penenberg D, Scher H, Yagoda A. Prognostic factors for survival of patients with advanced urothelial tumors treated with methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy. Cancer 1991;67:1525-31.
-
(1991)
Cancer
, vol.67
, pp. 1525-1531
-
-
Geller, N.L.1
Sternberg, C.N.2
Penenberg, D.3
Scher, H.4
Yagoda, A.5
-
9
-
-
0036125840
-
Future directions for gemcitabine in the treatment of genitourinary cancer
-
Vogelzang NJ. Future directions for gemcitabine in the treatment of genitourinary cancer. Sem Oncol 2002;29(1 Suppl 3):40-5.
-
(2002)
Sem Oncol
, vol.29
, Issue.1 SUPPL. 3
, pp. 40-45
-
-
Vogelzang, N.J.1
-
10
-
-
0036126022
-
Novel gemcitabine-containing triplets in the management of urothelial cancer
-
Hussain M, Vaishampayan U, Smith DC. Novel gemcitabine-containing triplets in the management of urothelial cancer. Sem Oncol 2002;29(1 Suppl 3):20-4.
-
(2002)
Sem Oncol
, vol.29
, Issue.1 SUPPL. 3
, pp. 20-24
-
-
Hussain, M.1
Vaishampayan, U.2
Smith, D.C.3
-
11
-
-
0034871427
-
Second-line treatment of advanced transitional cell carcinoma of the urothelial tract
-
Sternberg CN. Second-line treatment of advanced transitional cell carcinoma of the urothelial tract. Curr Opin Urol 2001;11(5):523-9.
-
(2001)
Curr Opin Urol
, vol.11
, Issue.5
, pp. 523-529
-
-
Sternberg, C.N.1
-
12
-
-
0036675237
-
New drugs and new approaches for the treatment of metastatic urothelial cancer
-
Calabrò F, Sternberg CN. New drugs and new approaches for the treatment of metastatic urothelial cancer. World J Urol 2002;20(3):158-66.
-
(2002)
World J Urol
, vol.20
, Issue.3
, pp. 158-166
-
-
Calabrò, F.1
Sternberg, C.N.2
-
13
-
-
0036739839
-
High-risk metastatic urothelial cancer: Chances for cure?
-
Calabrò F, Sternberg CN. High-risk metastatic urothelial cancer: chances for cure? Curr Opin Urol 2002;12(5):441-8.
-
(2002)
Curr Opin Urol
, vol.12
, Issue.5
, pp. 441-448
-
-
Calabrò, F.1
Sternberg, C.N.2
-
14
-
-
0033956528
-
Gemcitabine in bladder cancer
-
Sternberg CN. Gemcitabine in bladder cancer. Sem Oncol 2000;27(1):31-9.
-
(2000)
Sem Oncol
, vol.27
, Issue.1
, pp. 31-39
-
-
Sternberg, C.N.1
-
15
-
-
0036882090
-
The role of systemic chemotherapy in the management of muscle-invasive bladder cancer
-
Juffs HG, Moore MJ, Tannock IF. The role of systemic chemotherapy in the management of muscle-invasive bladder cancer. Lancet Oncol 2002;3(12):738-47.
-
(2002)
Lancet Oncol
, vol.3
, Issue.12
, pp. 738-747
-
-
Juffs, H.G.1
Moore, M.J.2
Tannock, I.F.3
-
16
-
-
0026746316
-
Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy
-
Bellmunt J, Albanell J, Gallego OS, Ribas A, Vicente P, Carulla J, et al. Carboplatin, methotrexate, and vinblastine in patients with bladder cancer who were ineligible for cisplatin-based chemotherapy. Cancer 1992;70:1974-9.
-
(1992)
Cancer
, vol.70
, pp. 1974-1979
-
-
Bellmunt, J.1
Albanell, J.2
Gallego, O.S.3
Ribas, A.4
Vicente, P.5
Carulla, J.6
-
17
-
-
0027482017
-
Carboplatin-based chemotherapy for bladder cancer
-
Waxman J, Barton C. Carboplatin-based chemotherapy for bladder cancer. Cancer Treat Rev 1993;19(Suppl C):21-5.
-
(1993)
Cancer Treat Rev
, vol.19
, Issue.SUPPL. C
, pp. 21-25
-
-
Waxman, J.1
Barton, C.2
-
18
-
-
0030865381
-
Lobaplatin in advanced urothelial tract tumors
-
The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC)
-
Sternberg CN, de Mulder P, Fossa S, Kaye S, Roberts T, Pawinsky A, et al. Lobaplatin in advanced urothelial tract tumors. The Genitourinary Group of the European Organization for Research and Treatment of Cancer (EORTC). Ann Oncol 1997;8(7):695-6.
-
(1997)
Ann Oncol
, vol.8
, Issue.7
, pp. 695-696
-
-
Sternberg, C.N.1
De Mulder, P.2
Fossa, S.3
Kaye, S.4
Roberts, T.5
Pawinsky, A.6
-
19
-
-
13844295293
-
A phase I and pharmacokinetic trial of oxaliplatin and gemcitabine in patients with solid tumours
-
Abstract
-
Mitchell P, Links M, Galettis P, Desai J, Zimet A, de Boer R, et al. A phase I and pharmacokinetic trial of oxaliplatin and gemcitabine in patients with solid tumours. Proc Amer Soc Clin Oncol 2002;21 [Abstract].
-
(2002)
Proc Amer Soc Clin Oncol
, pp. 21
-
-
Mitchell, P.1
Links, M.2
Galettis, P.3
Desai, J.4
Zimet, A.5
De Boer, R.6
-
20
-
-
0028174048
-
An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma
-
Witte RS, Elson P, Khandekar J. An Eastern Cooperative Oncology Group phase II trial of trimetrexate in the treatment of advanced urothelial carcinoma. Cancer 1994;73:688-92.
-
(1994)
Cancer
, vol.73
, pp. 688-692
-
-
Witte, R.S.1
Elson, P.2
Khandekar, J.3
-
21
-
-
0027463227
-
Oral piritrexim, an effective treatment for metastatic urothelial cancer
-
de Wit R, Kayne SB, Robert JT, et al. Oral piritrexim, an effective treatment for metastatic urothelial cancer. Br J Cancer 1993;67:388-90.
-
(1993)
Br J Cancer
, vol.67
, pp. 388-390
-
-
De Wit, R.1
Kayne, S.B.2
Robert, J.T.3
-
22
-
-
0030927578
-
Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder
-
Khorsand M, Lange J, Feun L, et al. Phase II trial of oral piritrexim in advanced, previously treated transitional cell cancer of bladder. Invest New Drugs 1997;15:157-63.
-
(1997)
Invest New Drugs
, vol.15
, pp. 157-163
-
-
Khorsand, M.1
Lange, J.2
Feun, L.3
-
23
-
-
0036125895
-
Brief communication: Use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer
-
Misset JL. Brief communication: use of the multitargeted antifolate pemetrexed (Alimta) in genitourinary cancer. Semin Oncol 2002;29(1 Suppl 3):36-9.
-
(2002)
Semin Oncol
, vol.29
, Issue.1 SUPPL. 3
, pp. 36-39
-
-
Misset, J.L.1
-
24
-
-
0034861227
-
Pemetrexed disodium: A novel antifolate clinically active against multiple solid tumors
-
Hanauske AR, Chen V, Paoletti P, Niyikiza C. Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors. Oncologist 2001;6(4):363-73.
-
(2001)
Oncologist
, vol.6
, Issue.4
, pp. 363-373
-
-
Hanauske, A.R.1
Chen, V.2
Paoletti, P.3
Niyikiza, C.4
-
25
-
-
0036261415
-
Future directions in the development of pemetrexed
-
Calvert H, Bunn Jr PA. Future directions in the development of pemetrexed. Sem Oncol 2002;29(2 Suppl 5):54-61.
-
(2002)
Sem Oncol
, vol.29
, Issue.2 SUPPL. 5
, pp. 54-61
-
-
Calvert, H.1
Bunn Jr., P.A.2
-
26
-
-
0001124267
-
A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder
-
Abstract
-
Paz-Ares L, Tabernero J, Moyano A, Rifa J, Gomez H, Marcuello E, et al. A phase II study of the multi-targeted antifolate, MTA (LY231514), in patients with advanced transitional cell carcinoma (TCC) of the bladder. Proc Annu Meet Am Soc Clin Oncol 1998;17:339a [Abstract].
-
(1998)
Proc Annu Meet Am Soc Clin Oncol
, vol.17
-
-
Paz-Ares, L.1
Tabernero, J.2
Moyano, A.3
Rifa, J.4
Gomez, H.5
Marcuello, E.6
-
27
-
-
0036261858
-
Folate status and the safety profile of antifolates
-
Calvert H. Folate status and the safety profile of antifolates. Sem Oncol 2002;29(2 Suppl 5):3-7.
-
(2002)
Sem Oncol
, vol.29
, Issue.2 SUPPL. 5
, pp. 3-7
-
-
Calvert, H.1
-
28
-
-
0037678524
-
Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers
-
Ref Type: In Press
-
Sternberg CN, Vogelzang NJ. Gemcitabine, paclitaxel, pemetrexed and other newer agents in urothelial and kidney cancers. Crit Rev Oncol Hematol 2003. Ref Type: In Press.
-
(2003)
Crit Rev Oncol Hematol
-
-
Sternberg, C.N.1
Vogelzang, N.J.2
-
29
-
-
0033857218
-
Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: Results of a large, randomized, multinational, multicenter, phase III study
-
von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol 2000;18(17):3068-77.
-
(2000)
J Clin Oncol
, vol.18
, Issue.17
, pp. 3068-3077
-
-
Von Der Maase, H.1
Hansen, S.W.2
Roberts, J.T.3
Dogliotti, L.4
Oliver, T.5
Moore, M.J.6
-
30
-
-
0027999651
-
Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: A phase II trial of the Eastern Cooperative Oncology Group
-
Roth BJ, Dreicer R, Einhorn LH. Significant activity of paclitaxel in advanced transitional cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group. J Clin Oncol 1994;12(11):2264-70.
-
(1994)
J Clin Oncol
, vol.12
, Issue.11
, pp. 2264-2270
-
-
Roth, B.J.1
Dreicer, R.2
Einhorn, L.H.3
-
31
-
-
0029853721
-
Paclitaxel in advanced urothelial carcinoma: Its role in patients with renal insufficiency and as salvage therapy
-
Dreicer R, Gustin DM, See WA, Williams RD. Paclitaxel in advanced urothelial carcinoma: its role in patients with renal insufficiency and as salvage therapy. J Urol 1996;156(5):1606-8.
-
(1996)
J Urol
, vol.156
, Issue.5
, pp. 1606-1608
-
-
Dreicer, R.1
Gustin, D.M.2
See, W.A.3
Williams, R.D.4
-
32
-
-
0002575775
-
Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer
-
Abstract
-
Murphy BA, Johnson DR, Smith J, Koch M, et al. Phase II trial of paclitaxel and cisplatin for metastatic or locally unresectable urothelial cancer. Proc Amer Soc Clin Oncol 1996;15 [Abstract].
-
(1996)
Proc Amer Soc Clin Oncol
, pp. 15
-
-
Murphy, B.A.1
Johnson, D.R.2
Smith, J.3
Koch, M.4
-
33
-
-
0033994219
-
Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: An Eastern Cooperative Oncology Group Study
-
Dreicer R, Manola J, Roth BJ, Cohen MB, Hatfield AK, Wilding G. Phase II study of cisplatin and paclitaxel in advanced carcinoma of the urothelium: an Eastern Cooperative Oncology Group Study. J Clin Oncol 2000;18(5):1058-61.
-
(2000)
J Clin Oncol
, vol.18
, Issue.5
, pp. 1058-1061
-
-
Dreicer, R.1
Manola, J.2
Roth, B.J.3
Cohen, M.B.4
Hatfield, A.K.5
Wilding, G.6
-
34
-
-
0033789641
-
Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC)
-
Burch PA, Richardson RL, Cha SS, Sargent DJ, Pitot HC, Kaur JS, et al. Phase II trial of combination paclitaxel and cisplatin in advanced urothelial carcinoma (UC). J Urol 2000;164:1538-42.
-
(2000)
J Urol
, vol.164
, pp. 1538-1542
-
-
Burch, P.A.1
Richardson, R.L.2
Cha, S.S.3
Sargent, D.J.4
Pitot, H.C.5
Kaur, J.S.6
-
35
-
-
0031005761
-
Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma
-
McCaffrey JA, Hilton S, Mazumdar M. Phase II trial of docetaxel in patients with advanced or metastatic transitional cell carcinoma. J Clin Oncol 1997;15(5):1853-7.
-
(1997)
J Clin Oncol
, vol.15
, Issue.5
, pp. 1853-1857
-
-
McCaffrey, J.A.1
Hilton, S.2
Mazumdar, M.3
-
36
-
-
0031786379
-
Docetaxel (Taxotere): An active agent in metastatic urothelial cancer results of a phase II study in non-chemotherapy pretreated patients
-
de Wit R, Kruit WH, Stoter G, de Boer M, Kerger J, Verweij J. Docetaxel (Taxotere): an active agent in metastatic urothelial cancer results of a phase II study in non-chemotherapy pretreated patients. Br J Cancer 1998;78(10):1342-5.
-
(1998)
Br J Cancer
, vol.78
, Issue.10
, pp. 1342-1345
-
-
De Wit, R.1
Kruit, W.H.2
Stoter, G.3
De Boer, M.4
Kerger, J.5
Verweij, J.6
-
37
-
-
0031752909
-
Docetaxel and cisplatin in metastatic urothelial cancer: A phase II study
-
Sengelov L, Kamby C, Lund B, Engelholm SA. Docetaxel and cisplatin in metastatic urothelial cancer: a phase II study. J Clin Oncol 1998;16(10):3392-7.
-
(1998)
J Clin Oncol
, vol.16
, Issue.10
, pp. 3392-3397
-
-
Sengelov, L.1
Kamby, C.2
Lund, B.3
Engelholm, S.A.4
-
38
-
-
0032779101
-
Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative
-
Dimopoulos MA, Bakoyannis C, Georgoulias V, Papadimitriou C, Moulopoulos LA, Deliveliotis C, et al. Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: a multicenter phase II study of the Hellenic Cooperative. Ann Oncol 1999;10(11):1385-8.
-
(1999)
Ann Oncol
, vol.10
, Issue.11
, pp. 1385-1388
-
-
Dimopoulos, M.A.1
Bakoyannis, C.2
Georgoulias, V.3
Papadimitriou, C.4
Moulopoulos, L.A.5
Deliveliotis, C.6
-
39
-
-
18244396648
-
Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer
-
Garcia del Muro X, Marcuello E, Guma J, Paz-Ares L, Climent MA, Carles J, et al. Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer. Br J Cancer 2002;86(3):326-30.
-
(2002)
Br J Cancer
, vol.86
, Issue.3
, pp. 326-330
-
-
Garcia Del Muro, X.1
Marcuello, E.2
Guma, J.3
Paz-Ares, L.4
Climent, M.A.5
Carles, J.6
-
40
-
-
0034741810
-
Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities
-
Fahy J. Modifications in the "upper" velbenamine part of the Vinca alkaloids have major implications for tubulin interacting activities. Curr Pharm Des 2001;7(13):1181-97.
-
(2001)
Curr Pharm Des
, vol.7
, Issue.13
, pp. 1181-1197
-
-
Fahy, J.1
-
41
-
-
0034517147
-
Preclinical and clinical trials of topoisomerase inhibitors
-
Saijo N. Preclinical and clinical trials of topoisomerase inhibitors. Ann NY Acad Sci 2000;922:92-9.
-
(2000)
Ann NY Acad Sci
, vol.922
, pp. 92-99
-
-
Saijo, N.1
-
42
-
-
0033199091
-
Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I
-
Yoshinari T, Ohkubo M, Fukasawa K, Egashira S, Hara Y, Matsumoto M, et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999;59(17):4271-5.
-
(1999)
Cancer Res
, vol.59
, Issue.17
, pp. 4271-4275
-
-
Yoshinari, T.1
Ohkubo, M.2
Fukasawa, K.3
Egashira, S.4
Hara, Y.5
Matsumoto, M.6
-
43
-
-
0034884824
-
Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D- glucopyranosyl)-5H-indolo[2,3-a]-pyrrolo[3,4-c]-carbazole-5,7(6H)-dione] against pediatric and adult central nervous system tumor xenografts
-
Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2- hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]- pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 2001;48(3):250-4.
-
(2001)
Cancer Chemother Pharmacol
, vol.48
, Issue.3
, pp. 250-254
-
-
Cavazos, C.M.1
Keir, S.T.2
Yoshinari, T.3
Bigner, D.D.4
Friedman, H.S.5
-
44
-
-
0035873915
-
Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors
-
European Organization for Research and Treatment of Cancer. Protocol No. 30924
-
Sternberg CN, de Mulder PHM, Schornagel JH, Théodore C, Fossa SD, van Oosterom AT, et al. Randomized phase III trial of high dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors. European Organization for Research and Treatment of Cancer. Protocol No. 30924. J Clin Oncol 2001;19(10):2638-46.
-
(2001)
J Clin Oncol
, vol.19
, Issue.10
, pp. 2638-2646
-
-
Sternberg, C.N.1
De Mulder, P.H.M.2
Schornagel, J.H.3
Théodore, C.4
Fossa, S.D.5
Van Oosterom, A.T.6
-
45
-
-
0036199749
-
The management of bladder cancer in the elderly
-
Sternberg CN, Calabrò F. The management of bladder cancer in the elderly. Tumori 2002;88(1 Suppl 1):S128-9.
-
(2002)
Tumori
, vol.88
, Issue.1 SUPPL. 1
-
-
Sternberg, C.N.1
Calabrò, F.2
-
46
-
-
0034773203
-
A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer
-
Bellmunt J, de Wit R, Albanell J, Baselga J. A feasibility study of carboplatin with fixed dose of gemcitabine in 'unfit' patients with advanced bladder cancer. Eur J Cancer 2001;37(17):2212-5.
-
(2001)
Eur J Cancer
, vol.37
, Issue.17
, pp. 2212-2215
-
-
Bellmunt, J.1
De Wit, R.2
Albanell, J.3
Baselga, J.4
-
47
-
-
0036125648
-
Gemcitabine doublets in advanced urothelial cancer
-
Stadler WM. Gemcitabine doublets in advanced urothelial cancer. Sem Oncol 2002;29(1 Suppl 3):15-9.
-
(2002)
Sem Oncol
, vol.29
, Issue.1 SUPPL. 3
, pp. 15-19
-
-
Stadler, W.M.1
-
48
-
-
0342758712
-
Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional cell carcinoma: The importance of survival as a clinical trial end point
-
Small EJ, Lew D, Redman BG, Petrylak DP, Hammond N, Gross HM, et al. Southwest Oncology Group Study of paclitaxel and carboplatin for advanced transitional cell carcinoma: the importance of survival as a clinical trial end point. J Clin Oncol 2000;18(13):2537-44.
-
(2000)
J Clin Oncol
, vol.18
, Issue.13
, pp. 2537-2544
-
-
Small, E.J.1
Lew, D.2
Redman, B.G.3
Petrylak, D.P.4
Hammond, N.5
Gross, H.M.6
-
49
-
-
0031962154
-
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: An active and tolerable outpatient regiment
-
Vaughn DJ, Malkowicz SB, Zoltick B, Mick R, Ramchandani P, Holroyde C, et al. Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regiment. J Clin Oncol 1998;16(1):255-60.
-
(1998)
J Clin Oncol
, vol.16
, Issue.1
, pp. 255-260
-
-
Vaughn, D.J.1
Malkowicz, S.B.2
Zoltick, B.3
Mick, R.4
Ramchandani, P.5
Holroyde, C.6
-
50
-
-
0031803705
-
Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma
-
Redman BG, Smith DC, Flaherty L, Du W, Hussain M. Phase II trial of paclitaxel and carboplatin in the treatment of advanced urothelial carcinoma. J Clin Oncol 1998;16(5):1844-8.
-
(1998)
J Clin Oncol
, vol.16
, Issue.5
, pp. 1844-1848
-
-
Redman, B.G.1
Smith, D.C.2
Flaherty, L.3
Du, W.4
Hussain, M.5
-
51
-
-
0035892761
-
Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy
-
[51 ] Sternberg CN, Calabrò F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with every-2-week gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer 2001;92(12):2993-8.
-
(2001)
Cancer
, vol.92
, Issue.12
, pp. 2993-2998
-
-
Sternberg, C.N.1
Calabrò, F.2
Pizzocaro, G.3
Marini, L.4
Schnetzer, S.5
Sella, A.6
-
52
-
-
0035876046
-
Paclitaxel and gemcitabine chemotherapy for adanced transitional-cell carcinoma of the urothelial tract: A phase II trial of the Minnie Pearl Cancer Research Network
-
Meluch AA, Greco FA, Burris III HA, O'Rourke T, Ortega G, Steis RG, et al. Paclitaxel and gemcitabine chemotherapy for adanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2001;19(12):3018-24.
-
(2001)
J Clin Oncol
, vol.19
, Issue.12
, pp. 3018-3024
-
-
Meluch, A.A.1
Greco, F.A.2
Burris III, H.A.3
O'Rourke, T.4
Ortega, G.5
Steis, R.G.6
-
53
-
-
0013240227
-
A hossier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder
-
Abstract
-
Parameswaran R, Fisch MJ, Ansari RH, Fox EP, Sweeney CJ, Einhorn LH. A hossier oncology group phase II study of weekly paclitaxel and gemcitabine in advanced transitional cell (TCC) carcinoma of the bladder. Proc Annu Meet Am Soc Clin Oncol 2001;20(1):200a [Abstract].
-
(2001)
Proc Annu Meet Am Soc Clin Oncol
, vol.20
, Issue.1
-
-
Parameswaran, R.1
Fisch, M.J.2
Ansari, R.H.3
Fox, E.P.4
Sweeney, C.J.5
Einhorn, L.H.6
-
54
-
-
0003365848
-
Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies
-
Abstract
-
Guardino AE, Srinivas S. Gemcitabine and paclitaxel as second line chemotherapy for advanced urothelial malignancies. Proc Annu Meet Am Soc Clin Oncol 2002;21(2):150b [Abstract].
-
(2002)
Proc Annu Meet Am Soc Clin Oncol
, vol.21
, Issue.2
-
-
Guardino, A.E.1
Srinivas, S.2
-
55
-
-
0010422261
-
Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma
-
Abstract
-
Fechner GH, Siener R, Reimann M, Strunk R, Golinski C, Heimbach D, et al. Randomized phase II trial of gemcitabine and paclitaxel with or without maintenance treatment in patients with cisplatin refractory transitional cell carcinoma. J Urol 2002;167(4 Suppl):284 [Abstract].
-
(2002)
J Urol
, vol.167
, Issue.4 SUPPL.
, pp. 284
-
-
Fechner, G.H.1
Siener, R.2
Reimann, M.3
Strunk, R.4
Golinski, C.5
Heimbach, D.6
-
56
-
-
4244198798
-
Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): A completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC)
-
Abstract
-
Kaufmann DS, Carducci MA, Kuzel T, Todd MB, Raghavan D, Oh WK, et al. Gemcitabine (G) and paclitaxel (P) every two weeks (GP2w): a completed multicenter phase II trial in locally advanced or metastatic urothelial cancer (UC). Proc Annu Meet Am Soc Clin Oncol 2002;21(1):192a [Abstract].
-
(2002)
Proc Annu Meet Am Soc Clin Oncol
, vol.21
, Issue.1
-
-
Kaufmann, D.S.1
Carducci, M.A.2
Kuzel, T.3
Todd, M.B.4
Raghavan, D.5
Oh, W.K.6
-
57
-
-
0000568613
-
Gemcitabine and docetaxel in advanced carcinoma of the urothelium: Reporto of a phase II Eastern Cooperative Oncology Group trial
-
Manola JB, Dreicer R, Wilding G. Gemcitabine and docetaxel in advanced carcinoma of the urothelium: reporto of a phase II Eastern Cooperative Oncology Group trial. Proc Annu Meet Am Soc Clin Oncol 2002;21(1):200a.
-
(2002)
Proc Annu Meet Am Soc Clin Oncol
, vol.21
, Issue.1
-
-
Manola, J.B.1
Dreicer, R.2
Wilding, G.3
-
58
-
-
0036052170
-
Triplet Combination Chemotherapy Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer
-
Bellmunt J, Cos J, Cleries R, Perez M, Ribas A, Eres N, et al. Triplet Combination Chemotherapy Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer. Cancer Invest 2002;20(5-6):673-85.
-
(2002)
Cancer Invest
, vol.20
, Issue.5-6
, pp. 673-685
-
-
Bellmunt, J.1
Cos, J.2
Cleries, R.3
Perez, M.4
Ribas, A.5
Eres, N.6
-
59
-
-
0034666030
-
Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium
-
Bellmunt J, Guillem V, Paz-Ares L, González-Larriba JL, Charles J, Batiste-Alentorn E, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. J Clin Oncol 2000;18(18):3247-55.
-
(2000)
J Clin Oncol
, vol.18
, Issue.18
, pp. 3247-3255
-
-
Bellmunt, J.1
Guillem, V.2
Paz-Ares, L.3
González-Larriba, J.L.4
Charles, J.5
Batiste-Alentorn, E.6
-
60
-
-
0043169600
-
New drugs and new approaches in metastatic bladder cancer
-
In press
-
Bellmunt J, de Wit R, Albiol S, Tabernero JM, Albanell J, Baselga J. New drugs and new approaches in metastatic bladder cancer. J Clin Oncol 2003. In press.
-
(2003)
J Clin Oncol
-
-
Bellmunt, J.1
De Wit, R.2
Albiol, S.3
Tabernero, J.M.4
Albanell, J.5
Baselga, J.6
-
61
-
-
0035339940
-
Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer
-
Hussain M, Vaishampayan U, Du W, Redman B, Smith DC. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J Clin Oncol 2001;19(9):2527-33.
-
(2001)
J Clin Oncol
, vol.19
, Issue.9
, pp. 2527-2533
-
-
Hussain, M.1
Vaishampayan, U.2
Du, W.3
Redman, B.4
Smith, D.C.5
-
62
-
-
0034177933
-
Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: Final report of a phase II trial evaluating two dosing schedules
-
Bajorin DF, McCaffrey JA, Dodd PM, Hilton S, Mazumdar M, Kelly WK, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. Cancer 2000;88(7):1671-8.
-
(2000)
Cancer
, vol.88
, Issue.7
, pp. 1671-1678
-
-
Bajorin, D.F.1
McCaffrey, J.A.2
Dodd, P.M.3
Hilton, S.4
Mazumdar, M.5
Kelly, W.K.6
-
63
-
-
0033956934
-
Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract
-
Dodd PM, McCaffrey JA, Hilton S, Mazumdar M, Herr H, Kelly WK, et al. Phase I evaluation of sequential doxorubicin gemcitabine then ifosfamide paclitaxel cisplatin for patients with unresectable or metastatic transitional cell carcinoma of the urothelial tract. J Clin Oncol 2000;18(4):840-6.
-
(2000)
J Clin Oncol
, vol.18
, Issue.4
, pp. 840-846
-
-
Dodd, P.M.1
McCaffrey, J.A.2
Hilton, S.3
Mazumdar, M.4
Herr, H.5
Kelly, W.K.6
-
64
-
-
0034614637
-
The hallmarks of cancer
-
Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100(1):57-70.
-
(2000)
Cell
, vol.100
, Issue.1
, pp. 57-70
-
-
Hanahan, D.1
Weinberg, R.A.2
-
65
-
-
0034795435
-
Farnesyl transferase inhibitors - A novel therapy for breast cancer
-
Johnston SR, Kelland LR. Farnesyl transferase inhibitors - a novel therapy for breast cancer. Endocr Relat Cancer 2001;8(3):227-35.
-
(2001)
Endocr Relat Cancer
, vol.8
, Issue.3
, pp. 227-235
-
-
Johnston, S.R.1
Kelland, L.R.2
-
66
-
-
0036489947
-
Current progress on farnesyl protein transferase inhibitors
-
Singh SB, Lingham RB. Current progress on farnesyl protein transferase inhibitors. Curr Opin Drug Discov Devel 2002;5(2):225-44.
-
(2002)
Curr Opin Drug Discov Devel
, vol.5
, Issue.2
, pp. 225-244
-
-
Singh, S.B.1
Lingham, R.B.2
-
67
-
-
0001139688
-
NCIC CTG IND. 128: A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional Cell Carcinoma of the urothelial tract failing prior chemotherapy
-
Abstract
-
Winquist E, Moore MJ, Chi K, Ernst S, Hirte H, Iscoe N, et al. NCIC CTG IND. 128: A phase II study of a farnesyl transferase inhibitor (SCH 66336) in patients with unresectable or metastatic transitional Cell Carcinoma of the urothelial tract failing prior chemotherapy. Proc Annu Meet Am Soc Clin Oncol 2001;20(1):197a [Abstract].
-
(2001)
Proc Annu Meet Am Soc Clin Oncol
, vol.20
, Issue.1
-
-
Winquist, E.1
Moore, M.J.2
Chi, K.3
Ernst, S.4
Hirte, H.5
Iscoe, N.6
-
68
-
-
0036489885
-
Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - Clinical progress
-
Renhowe PA. Inhibitors of growth factor receptor kinase-dependent signaling pathways in anticancer chemotherapy - clinical progress. Curr Opin Drug Discov Devel 2002;5(2):214-24.
-
(2002)
Curr Opin Drug Discov Devel
, vol.5
, Issue.2
, pp. 214-224
-
-
Renhowe, P.A.1
-
69
-
-
0036500831
-
Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: A new paradigm for cancer therapy
-
Herbst RS, Shin DM. Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 2002;94(5):1593-611.
-
(2002)
Cancer
, vol.94
, Issue.5
, pp. 1593-1611
-
-
Herbst, R.S.1
Shin, D.M.2
-
70
-
-
0036214044
-
The ErbB receptor family: A therapeutic target for cancer
-
de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med 2002;8(4):S19-26.
-
(2002)
Trends Mol Med
, vol.8
, Issue.4
-
-
De Bono, J.S.1
Rowinsky, E.K.2
-
71
-
-
0002823211
-
Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR)
-
Abstract
-
Saltz L, Rubin M, Hochster H, Tchekmeydian NS, Waksal H, Needle M, et al. Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11-refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (EGFR). Proc Annu Meet Am Soc Clin Oncol 2001;20(1):3a [Abstract].
-
(2001)
Proc Annu Meet Am Soc Clin Oncol
, vol.20
, Issue.1
-
-
Saltz, L.1
Rubin, M.2
Hochster, H.3
Tchekmeydian, N.S.4
Waksal, H.5
Needle, M.6
-
72
-
-
0035409904
-
IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer
-
Herbst RS, Kim ES, Harari PM. IMC-C225, an anti-epidermal growth factor receptor monoclonal antibody, for treatment of head and neck cancer. Expert Opin Biol Ther 2001;1(4):719-32.
-
(2001)
Expert Opin Biol Ther
, vol.1
, Issue.4
, pp. 719-732
-
-
Herbst, R.S.1
Kim, E.S.2
Harari, P.M.3
-
73
-
-
0034489116
-
Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma
-
Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti-epidermal growth factor receptor monoclonal antibody ImClone C225 in mice with metastatic human bladder transitional cell carcinoma. Clin Cancer Res 2000;6(12):4874-84.
-
(2000)
Clin Cancer Res
, vol.6
, Issue.12
, pp. 4874-4884
-
-
Inoue, K.1
Slaton, J.W.2
Perrotte, P.3
-
74
-
-
0035869407
-
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2
-
Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344(11):783-92.
-
(2001)
N Engl J Med
, vol.344
, Issue.11
, pp. 783-792
-
-
Slamon, D.J.1
Leyland-Jones, B.2
Shak, S.3
Fuchs, H.4
Paton, V.5
Bajamonde, A.6
-
75
-
-
0034890387
-
Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: Prognostic significance and comparative analysis in primary and metastatic tumors
-
Jimenez RE, Hussain M, Bianco FJJ, Vaishampayan U, Tabazcka P, Sakr WA, et al. Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin Cancer Res 2001;7(8):2440-7.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.8
, pp. 2440-2447
-
-
Jimenez, R.E.1
Hussain, M.2
Bianco, F.J.J.3
Vaishampayan, U.4
Tabazcka, P.5
Sakr, W.A.6
-
76
-
-
0034879275
-
Mechanism of action of anti-HER2 monoclonal antibodies
-
Baselga J, Albanell J. Mechanism of action of anti-HER2 monoclonal antibodies. Ann Oncol 2001;12(Suppl 1):S35-41.
-
(2001)
Ann Oncol
, vol.12
, Issue.1 SUPPL.
-
-
Baselga, J.1
Albanell, J.2
-
77
-
-
0036721561
-
Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma?
-
Gandour-Edwards R, Lara PNJ, Folkins AK, LaSalle JM, Beckett L, Li Y, et al. Does HER2/neu expression provide prognostic information in patients with advanced urothelial carcinoma? Cancer 2002;95(5):1009-15.
-
(2002)
Cancer
, vol.95
, Issue.5
, pp. 1009-1015
-
-
Gandour-Edwards, R.1
Lara, P.N.J.2
Folkins, A.K.3
LaSalle, J.M.4
Beckett, L.5
Li, Y.6
-
78
-
-
0035992688
-
Oblimersen Bcl-2 antisense: Facilitating apoptosis in anticancer treatment
-
Klasa RJ, Gillum AM, Klem RE, Frankel SR. Oblimersen Bcl-2 antisense: facilitating apoptosis in anticancer treatment. Antisense Nucleic Acid Drug Dev 2002;12(3):193-213.
-
(2002)
Antisense Nucleic Acid Drug Dev
, vol.12
, Issue.3
, pp. 193-213
-
-
Klasa, R.J.1
Gillum, A.M.2
Klem, R.E.3
Frankel, S.R.4
-
79
-
-
0038786580
-
Apoptosis-targeted therapies for cancer
-
Reed JC. Apoptosis-targeted therapies for cancer. Cancer Cell 2003;3(1):17-22.
-
(2003)
Cancer Cell
, vol.3
, Issue.1
, pp. 17-22
-
-
Reed, J.C.1
-
80
-
-
0036716281
-
The Bcl-2 family: Regulators of the cellular life-or-death switch
-
Cory S, Adams J. The Bcl-2 family: regulators of the cellular life-or-death switch. Nature Reviews 2002;2:647-56.
-
(2002)
Nature Reviews
, vol.2
, pp. 647-656
-
-
Cory, S.1
Adams, J.2
-
81
-
-
0035678781
-
A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer
-
Chi KN, Gleave ME, Klasa R, Murray N, Bryce C, Lopes de Menezes DE, et al. A phase I dose-finding study of combined treatment with an antisense Bcl-2 oligonucleotide (Genasense) and mitoxantrone in patients with metastatic hormone-refractory prostate cancer. Clin Cancer Res 2001;7(12):3920-7.
-
(2001)
Clin Cancer Res
, vol.7
, Issue.12
, pp. 3920-3927
-
-
Chi, K.N.1
Gleave, M.E.2
Klasa, R.3
Murray, N.4
Bryce, C.5
Lopes De Menezes, D.E.6
-
82
-
-
0035529043
-
Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy
-
Qureshi KN, Griffiths TR, Robinson MC, Marsh C, Roberts JT, Lunec J, et al. Combined p21WAF1/CIP1 and p53 overexpression predict improved survival in muscle-invasive bladder cancer treated by radical radiotherapy. Int J Radiat Oncol Biol Phys 2001;51(5):1234-40.
-
(2001)
Int J Radiat Oncol Biol Phys
, vol.51
, Issue.5
, pp. 1234-1240
-
-
Qureshi, K.N.1
Griffiths, T.R.2
Robinson, M.C.3
Marsh, C.4
Roberts, J.T.5
Lunec, J.6
-
83
-
-
0032521376
-
Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53
-
Cote RJ, Dunn MD, Chatterjee SJ, Stein JP, Shi SR, Tran QC, et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 1998;58(6):1090-4.
-
(1998)
Cancer Res
, vol.58
, Issue.6
, pp. 1090-1094
-
-
Cote, R.J.1
Dunn, M.D.2
Chatterjee, S.J.3
Stein, J.P.4
Shi, S.R.5
Tran, Q.C.6
-
84
-
-
0030011128
-
Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21
-
Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. Nature 1996;381(6584):713-6.
-
(1996)
Nature
, vol.381
, Issue.6584
, pp. 713-716
-
-
Waldman, T.1
Lengauer, C.2
Kinzler, K.W.3
Vogelstein, B.4
-
85
-
-
0033887925
-
Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinoma
-
Komhoff M. Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinoma. Am J Pathol 2000;157(1):29-35.
-
(2000)
Am J Pathol
, vol.157
, Issue.1
, pp. 29-35
-
-
Komhoff, M.1
-
86
-
-
0034530889
-
The contributions of cyclooxygenase-2 to tumor angiogenesis
-
Gately S. The contributions of cyclooxygenase-2 to tumor angiogenesis. Cancer and Metastastis Reviews 2000;19(1-2):19-27.
-
(2000)
Cancer and Metastastis Reviews
, vol.19
, Issue.1-2
, pp. 19-27
-
-
Gately, S.1
|